Modified R-DAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Rigacci, L. [1 ]
Fabbri, A. [2 ]
Mappa, S. [1 ]
Nassi, L. [1 ]
Lenoci, M. [2 ]
Puccini, B. [1 ]
Alterini, R. [1 ]
Chitarrelli, I [2 ]
Carrai, V [1 ]
Lauria, F. [2 ]
Bosi, A. [1 ]
机构：
[1] Univ Florence, Florence Azienda Osped, Dept Hematol, I-50121 Florence, Italy
[2] Univ Siena, Siena Azienda Osped, Dept Hematol, I-53100 Siena, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Westin, Jason
    Maris, Michael B.
    Jacobson, Caron A.
    Patel, Prapti
    Lakhani, Nehal
    Harb, Wael
    Patel-Donnelly, Dipti
    McCaul, Kelly
    Escobar, Carolina
    Klencke, Barbara
    Al-Katib, Ayad M.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (01): : 52 - 59
  • [22] R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome
    Martin, Alejandro
    Caballero, Maria-Dolores
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (05): : 744 - 744
  • [23] The efficacy of R-ICE therapy as a salvage treatment for relapse and refractory diffuse large B-Cell lymphoma
    Kodaira, Makoto
    Yokoyama, Masahiro
    Asai, Hiroaki
    Yamada, Shuhei
    Ueda, Kyoko
    Myojo, Tomohiro
    Nishimura, Tomoko
    Mishima, Yuko
    Sakajiri, Sakura
    Takeuchi, Kengo
    Saotome, Takashi
    Terui, Yasuhito
    Takahashi, Shunji
    Hatake, Kiyohiko
    [J]. BLOOD, 2007, 110 (11) : 180B - 180B
  • [24] Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma
    Shen, Qiu-Dan
    Wang, Li
    Zhu, Hua-Yuan
    Liang, Jin-Hua
    Xia, Yi
    Wu, Jia-Zhu
    Fan, Lei
    Li, Jian-Yong
    Xu, Wei
    [J]. JOURNAL OF CANCER, 2021, 12 (01): : 163 - 169
  • [25] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    [J]. SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [26] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph P.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason R.
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, S. Ronan
    Ho, P. Joy p
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Pantano, Serafino
    Pacaud, Lida B.
    Awasthi, Rakesh
    Chu, Jufen
    Anak, Ozlem
    Salles, Gilles
    Maziarz, Richard T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01): : 45 - 56
  • [27] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
  • [28] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    [J]. BLOOD, 2022, 140 : 7906 - 7907
  • [29] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [30] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
12345